Makda S. Gebre
A5081788452- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Immunotherapy and Immune Responses
- Animal Virus Infections Studies
- SARS-CoV-2 detection and testing
- Virus-based gene therapy research
- Long-Term Effects of COVID-19
- Viral Infections and Vectors
- Mosquito-borne diseases and control
- Viral gastroenteritis research and epidemiology
- Cytomegalovirus and herpesvirus research
- Viral Infections and Outbreaks Research
- RNA Interference and Gene Delivery
- Virology and Viral Diseases
- Cancer Immunotherapy and Biomarkers
- HIV Research and Treatment
- Reproductive System and Pregnancy
- Vaccine Coverage and Hesitancy
- Plant Virus Research Studies
- Lymphoma Diagnosis and Treatment
- Respiratory Support and Mechanisms
- Autopsy Techniques and Outcomes
- vaccines and immunoinformatics approaches
- Animal Nutrition and Physiology
- CRISPR and Genetic Engineering
Beth Israel Deaconess Medical Center
2019-2022
Harvard University
2018-2021
Ragon Institute of MGH, MIT and Harvard
2020-2021
Utah State University
2016-2020
The global coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome 2 (SARS-CoV-2) has made the development of a vaccine top biomedical priority. In this study, we developed series DNA candidates expressing different forms SARS-CoV-2 spike (S) protein and evaluated them in 35 rhesus macaques. Vaccinated animals humoral cellular immune responses, including neutralizing antibody titers at levels comparable to those found convalescent humans macaques infected...
An understanding of protective immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical for vaccine and public health strategies aimed at ending the global disease 2019 (COVID-19) pandemic. A key unanswered question whether infection with SARS-CoV-2 results in against reexposure. We developed a rhesus macaque model observed that macaques had high viral loads upper lower tract, humoral cellular immune responses, pathologic evidence pneumonia. After initial...
Pregnant women are at increased risk of morbidity and mortality from COVID-19 but have been excluded the phase 3 vaccine trials. Data on safety immunogenicity in these populations therefore limited.
Abstract Coronavirus disease 2019 (COVID-19) in humans is often a clinically mild illness, but some individuals develop severe pneumonia, respiratory failure and death 1–4 . Studies of acute syndrome coronavirus 2 (SARS-CoV-2) infection hamsters 5–7 nonhuman primates 8–10 have generally reported clinical disease, preclinical SARS-CoV-2 vaccine studies demonstrated reduction viral replication the upper lower tracts 11–13 Here we show that high-dose intranasal results including high levels...
Control of the global COVID-19 pandemic will require development and deployment safe effective vaccines.To evaluate immunogenicity Ad26.COV2.S vaccine (Janssen/Johnson & Johnson) in humans, including kinetics, magnitude, phenotype SARS-CoV-2 spike-specific humoral cellular immune responses.Twenty-five participants were enrolled from July 29, 2020, to August 7, follow-up for this day 71 interim analysis was completed on October 3, 2020; assess durability continue 2 years. This study conducted...
Abstract The CVnCoV (CureVac) mRNA vaccine for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was recently evaluated in a phase 2b/3 efficacy trial humans 1 . CV2CoV is second-generation containing non-modified nucleosides but with optimized non-coding regions and enhanced antigen expression. Here we report the results of head-to-head comparison immunogenicity protective non-human primates. We immunized 18 cynomolgus macaques two doses 12 μg lipid nanoparticle-formulated or...
Pseudotyped viruses are valuable tools for studying virulent or lethal viral pathogens that need to be handled in biosafety level 3 (BSL-3) higher facilities. With the explosive spread of coronavirus disease 2019 (COVID-19) pandemic, establishment a BSL-2 adapted SARS-CoV-2 pseudovirus neutralization assay is needed facilitate development countermeasures. Here we describe an approach generate single-round lentiviral vector-based pseudovirus, which produced signal more than 2 logs above...
Abstract Antibodies serve as biomarkers of infection, but if sustained can confer long-term immunity. Yet, for most clinically approved vaccines, binding antibody titers only a surrogate protection. Instead, the ability vaccine induced antibodies to neutralize or mediate Fc-effector functions is mechanistically linked While evidence has begun point persisting responses among SARS-CoV-2 infected individuals, cases re-infection have emerge, calling protective nature humoral immunity against...
To combat the HIV epidemic and emerging threats such as SARS-CoV-2, immunization strategies are needed that elicit protection at mucosal portals of pathogen entry. Immunization directly through airway surfaces is effective in driving immunity, but poor vaccine uptake across mucus epithelial lining a limitation. The major blood protein albumin constitutively transcytosed bidirectionally epithelium interactions with neonatal Fc receptors (FcRn). Exploiting this biology, here, we demonstrate...
mRNA vaccines can be developed and produced quickly, making them prime candidates for immediate outbreak responses. Furthermore, clinical trials have demonstrated rapid protection following vaccination. Thus, we sought to investigate how quickly elicit antibody responses compared other vaccine modalities. We first the immune kinetics of DNA expressing SARS-CoV-2 spike in mice. observed induction antigen-specific binding neutralizing antibodies by day 5 (4 µg/mouse), but not (50 immunization....
To determine the feasibility and safety of ultrasound-guided minimally invasive autopsy in COVID-19 patients. 60 patients who expired between 04/22/2020–05/06/2020 due to were considered for inclusion study, based on availability study staff. Minimally was performed with 14G core biopsies through a 13G coaxial needle. The protocol required 20 cores liver, 30 lung, 12 spleen, heart, kidney, 4 breast, testis, 2 skeletal muscle, fat total 112 per patient. Quality samples evaluated by number,...
ABSTRACT Interim immunogenicity and efficacy data for the Ad26.COV2.S vaccine COVID-19 have recently been reported 1-3 . We describe here 8-month durability of humoral cellular immune responses in 20 individuals who received one or two doses 5×10 10 vp 11 5 participants placebo 2 evaluated antibody T cell on day 239, which was 8 months after single-shot regimen (N=10) 6 two-shot (N=10), although present study not powered to compare these regimens 3 also report neutralizing against parental...
Obesity is a key correlate of severe SARS-CoV-2 outcomes while the role obesity on risk infection, symptom phenotype, and immune response remain poorly defined. We examined data from prospective cohort study to address these questions. Serostatus, body mass index, demographics, comorbidities, prior COVID-19 compatible symptoms were assessed at baseline serostatus monthly thereafter. immunoassays included an IgG ELISA targeting spike RBD, multiarray Luminex 20 viral antigens, pseudovirus...
Abstract The rapid spread of the highly mutated SARS-CoV-2 Omicron variant has raised substantial concerns about protective efficacy currently available vaccines. We assessed Omicron-specific humoral and cellular immune responses in 65 individuals who were vaccinated with two immunizations BNT162b2 boosted after at least 6 months either Ad26.COV2.S (Johnson & Johnson; N=41) or (Pfizer; N=24) (Table S1).